Retatrutide, a new dual activator of the GLP-1 target and glucose-dependent secreted polypeptide (GIP) binding site , is demonstrating promising outcomes in preliminary clinical studies. Ongoing https://telebookmarks.com/story11955369/retatrutide-emerging-research-and-projected-therapeutic-uses